Free Trial
NASDAQ:EPRX

Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis

Eupraxia Pharmaceuticals logo
$3.93 0.00 (0.00%)
Closing price 05/30/2025 03:59 PM Eastern
Extended Trading
$3.89 -0.04 (-1.02%)
As of 05/30/2025 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Eupraxia Pharmaceuticals Stock (NASDAQ:EPRX)

Key Stats

Today's Range
$3.82
$3.93
50-Day Range
$2.93
$4.10
52-Week Range
$2.20
$4.48
Volume
7,576 shs
Average Volume
13,100 shs
Market Capitalization
$140.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50
Consensus Rating
Buy

Company Overview

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Eupraxia Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

EPRX MarketRank™: 

Eupraxia Pharmaceuticals scored higher than 43% of companies evaluated by MarketBeat, and ranked 663rd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eupraxia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Eupraxia Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Eupraxia Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Eupraxia Pharmaceuticals are expected to grow in the coming year, from ($0.67) to ($0.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eupraxia Pharmaceuticals is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eupraxia Pharmaceuticals is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Eupraxia Pharmaceuticals has a P/B Ratio of 131.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Eupraxia Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.59% of the float of Eupraxia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Eupraxia Pharmaceuticals has recently increased by 17.52%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Eupraxia Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Eupraxia Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.59% of the float of Eupraxia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Eupraxia Pharmaceuticals has recently increased by 17.52%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Eupraxia Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Eupraxia Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for EPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Eupraxia Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
Receive EPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EPRX Stock News Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More Headlines

EPRX Stock Analysis - Frequently Asked Questions

Eupraxia Pharmaceuticals' stock was trading at $3.17 on January 1st, 2025. Since then, EPRX shares have increased by 24.0% and is now trading at $3.93.
View the best growth stocks for 2025 here
.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) announced its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02.

Top institutional shareholders of Eupraxia Pharmaceuticals include Scotia Capital Inc. (4.33%) and Royal Bank of Canada (0.96%).

Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eupraxia Pharmaceuticals investors own include Aeterna Zentaris (AEZS), BlackBerry (BB), Bausch Health Companies (BHC), Bitfarms (BITF), Ballard Power Systems (BLDP), Cardiol Therapeutics (CRDL) and Fury Gold Mines (FURY).

Company Calendar

Last Earnings
5/06/2025
Today
5/30/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EPRX
Previous Symbol
NASDAQ:EPRX
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.50
High Stock Price Target
$12.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+167.2%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$28.22 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.03 per share
Price / Book
131.00

Miscellaneous

Free Float
N/A
Market Cap
$140.89 million
Optionable
N/A
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:EPRX) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners